Cancer Therapies: A Global Market Report
San Jose, CA (PRWEB) February 18, 2009
Cancer therapies are geared towards controlling the growth of cancerous tumors, and preventing the spread of cancer to other organs of the body. Cancer care is becoming a prime concern among national health authorities, in both developed and developing countries alike, leading to significant investments in developing and improving the healthcare system's screening systems, and abilities. Standard cancer treatments such as chemotherapy, radiation therapy, surgery, given their relatively higher side effects and disadvantages, will likely be brushed aside by new biotherapy and immunological treatments, which are expected to spruce up growth. The market for world cancer therapies continues to gain traction as companies explore advancements and improvements in drug delivery techniques translating to greater market opportunity.
Technological developments in proteomics sciences, genomics, and transcriptomics, and a better understanding of pathologies, have lowered the entry barriers in cancer therapy research. This has encouraged companies to invest in new research and development projects, and has paved the way for identifying and validating new therapeutic drugs, which were hitherto kept under the wraps. Developments in toxicity and preclinical studies, coupled with the development of high-throughput screening, oral delivery formulations, chemical synthesis, cancer vaccines and molecular libraries, and improvements in characterizing and producing biological molecules, make cancer therapies a promising market.
Due to improved treatment outcomes, targeted therapies have outpaced chemotherapy to become the leading therapy class in the cancer treatment market. Consequently, worldwide targeted therapies market is expected to significantly increase during the next few years, as stated by the recent report published by Global Industry Analysts, Inc. By 2015, in addition to the already existing Rituxan, Herceptin, and Gleevec; new targeted therapies, such as Avastin, Tykerb, Nexavar, and Tarceva, are expected to make their way to the top 20 cancer therapeutics. Chemotherapy is expected to get a fresh lease of life, given the imminent availability of generic versions of cytotoxic drugs, which are likely to lose their patent protection in the upcoming years. Also, the efficacy of chemotherapeutic drugs in combination with targeted, is being researched, and is found to offer high levels of therapeutic efficacies. Riding on this positive note, global market for chemotherapy is expected to perform considerably well by 2012.
Key players dominating the global cancer therapies market include Abraxis Biosciences Inc, Amgen Inc, Astrazeneca Plc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corp, Cell Therapeutics Inc, Chugai Pharmaceutical Co Ltd., Eli Lilly, Genentech Inc, Genzyme Corp, Glaxosmithkline Plc, Imclone systems Inc, Merck & Co., Novartis, Pfizer Inc, Roche, Sanofi-Aventis, Seattle Genetics Inc, Takeda Pharmaceutical Company Limited, Schering Plough Corporation, OSI Pharmaceuticals Inc. and Wyeth Pharmaceuticals, among others.
The report titled "Cancer Therapies: A Global Market Report" published by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, new drug approvals and trials, product overview, key market trends, product introductions/innovations, profiles of major players and recent industry activity. The report analyzes market data and provides analytics in value sales for Global Cancer Therapies market. The study analyzes the Cancer Therapies market by the following product segments - Targeted Therapy, Chemotherapy, Hormone Therapy and Immunotherapy.
For more details about this research report, please visit http://www.strategyr.com/Cancer_Therapies_Market_Report.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Email press @ StrategyR.com
Web Site http://www.StrategyR.com